[1] European Association for the Study of the Liver. EASL Clinical Practice Guidelines on acute-on-chronic liver failure[J]. J Hepatol, 2023,79(2):461-491.
[2] Mezzano G, Juanola A, Cardenas A, et al. Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis[J]. Gut, 2022,71(1):148-155.
[3] Arroyo V, Moreau R, Kamath P S, et al. Acute-on-chronic liver failure in cirrhosis[J]. Nat Rev Dis Primers, 2016,2:16041.
[4] Sundaram V, Shah P, Wong R J, et al. Patients with acute on chronic liver failure grade 3 have greater 14-day waitlist mortality than status-1a patients[J]. Hepatology, 2019,70(1):334-345.
[5] Carpentier B, Gautier A, Legallais C. Artificial and bioartificial liver devices: present and future[J]. Gut, 2009,58(12):1690-1702.
[6] Chen H S, Joo D J, Shaheen M, et al. Randomized trial of spheroid reservoir bioartificial liver in porcine model of posthepatectomy liver failure[J]. Hepatology, 2019,69(1):329-342.
[7] Thompson J, Jones N, Al-Khafaji A, et al. Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: a multinational, prospective, controlled, randomized trial[J]. Liver Transpl, 2018,24(3):380-393.
[8] Huang P, Zhang L, Gao Y, et al. Direct reprogramming of human fibroblasts to functional and expandable hepatocytes[J]. Cell Stem Cell, 2014,14(3):370-384.
[9] Shi X L, Gao Y, Yan Y, et al. Improved survival of porcine acute liver failure by a bioartificial liver device implanted with induced human functional hepatocytes[J]. Cell Res, 2016, 26(2):206-216.
[10] Wang Y, Zheng Q, Sun Z, et al. Reversal of liver failure using a bioartificial liver device implanted with clinical-grade human-induced hepatocytes[J]. Cell Stem Cell, 2023, 30(5):617-631. e618.
[11] Zhang K, Zhang L, Liu W, et al. In vitro expansion of primary human hepatocytes with efficient liver repopulation capacity[J]. Cell Stem Cell, 2018, 23(6):806-819. e4.
[12] Yuan X, Wu J, Sun Z, et al. Preclinical efficacy and safety of encapsulated proliferating human hepatocyte organoids in treating liver failure[J]. Cell Stem Cell, 2024, 31(4):484-498. e5.
[13] Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis[J]. Gastroenterology, 2013,144(7): 1426-1437. 1437.e1-9.
[14] Yamaguchi H, Yoneyama Y, Ichimura K, et al. Reversal of ACLF and ALF using whole blood extracorporeal system combining HLA-depleted liver organoids with granulocyte-monocyte apheresis[J]. J Hepatol, 2026, 84(2):293-307.
[15] Shinozawa T, Kimura M, Cai Y, et al. High-fidelity drug-induced liver injury screen using human pluripotent stem cell-derived organoids[J]. Gastroenterology, 2021,160(3):831-846.e10.
[16] Dai Z S, Zhang M, Deng Y Y, et al. Efficacy of a novel artificial liver versatile plasma purification system in patients with acute-on-chronic liver failure. World J Gastroenterol. 2025,31(14):103892.
[17] Soreide J A, Deshpande R. Post-hepatectomy liver failure (PHLF)-recent advances in prevention and clinical management[J]. Eur J Surg Oncol, 2021, 47(2):216-224.
[18] Clavien P A, Petrowsky H, DeOliveira M L, et al. Strategies for safer liver surgery and partial liver transplantation[J]. N Engl J Med, 2007,356(15):1545-1559.
[19] Tao Y, Wang Y, Wang M, et al. Mesenchymal stem cells alleviate acute liver failure through regulating hepatocyte apoptosis and macrophage polarization[J]. J Clin Transl Hepatol, 2024, 12(6): 571-580.
[20] Huang Y, Cheng R, Wang G, et al. Harnessing mesenchymal stromal cells for liver disease therapy: from mechanistic discoveries to clinical breakthroughs[J]. Front Med (Lausanne),2026, 12: 1677021.
[21] Huang W, Li Y, Chen P, et al. Mesenchymal stem cell therapy as a game-changer in liver diseases: review of current clinical trials[J]. Stem Cell Res Ther, 2025,16(1):3.
[22] Yagi H, Fukumitsu K, Fukuda K, et al. Human-scale whole-organ bioengineering for liver transplantation: a regenerative medicine approach[J]. Cell Transplant, 2013,22(2):231-242.
[23] Roger V, Balladur P, Honiger J, et al. Internal bioartificial liver with xenogeneic hepatocytes prevents death from acute liver failure: an experimental study[J]. Ann Surg, 1998, 228(1):1-7.
[24] Zhang W, Xu Q, Xu K, et al. Genetically engineered pig-to-human liver xenotransplantation[J]. J Hepatol,2026,84(3):587-598. |
